PT1159003E - Anti-tnf alfa na terapêutica da asma resistente a esteróides - Google Patents

Anti-tnf alfa na terapêutica da asma resistente a esteróides Download PDF

Info

Publication number
PT1159003E
PT1159003E PT00912065T PT00912065T PT1159003E PT 1159003 E PT1159003 E PT 1159003E PT 00912065 T PT00912065 T PT 00912065T PT 00912065 T PT00912065 T PT 00912065T PT 1159003 E PT1159003 E PT 1159003E
Authority
PT
Portugal
Prior art keywords
antibody
antigen
ιαι
binding fragment
tnfî
Prior art date
Application number
PT00912065T
Other languages
English (en)
Portuguese (pt)
Inventor
George Treacy
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of PT1159003E publication Critical patent/PT1159003E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT00912065T 1999-03-02 2000-03-01 Anti-tnf alfa na terapêutica da asma resistente a esteróides PT1159003E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26095399A 1999-03-02 1999-03-02
US46569199A 1999-12-17 1999-12-17

Publications (1)

Publication Number Publication Date
PT1159003E true PT1159003E (pt) 2011-02-22

Family

ID=26948290

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00912065T PT1159003E (pt) 1999-03-02 2000-03-01 Anti-tnf alfa na terapêutica da asma resistente a esteróides

Country Status (10)

Country Link
US (3) US20010021381A1 (https=)
EP (1) EP1159003B1 (https=)
JP (2) JP2002538170A (https=)
AT (1) ATE488250T1 (https=)
AU (1) AU756677B2 (https=)
CA (1) CA2364026C (https=)
DE (1) DE60045240D1 (https=)
DK (1) DK1159003T3 (https=)
PT (1) PT1159003E (https=)
WO (1) WO2000051637A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115804821A (zh) * 2022-12-19 2023-03-17 新疆维吾尔药业有限责任公司 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
WO2004071527A1 (en) * 2003-02-11 2004-08-26 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
US20090110679A1 (en) * 2007-07-13 2009-04-30 Luk-Chiu Li Methods and compositions for pulmonary administration of a TNFa inhibitor
MX2010012473A (es) 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
DK2676137T3 (en) * 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822776A (en) * 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6419927B1 (en) * 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US6309640B1 (en) * 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0288088B1 (en) * 1987-04-24 1994-03-09 Teijin Limited Detection of tumor necrosis factor; monoclonal antibody and kit
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
EP1097945B1 (en) * 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE4139733A1 (de) * 1991-11-28 1993-06-03 Schering Ag Carbacyclinderivate als mittel zur behandlung von krankheitsbildern, die zum atopie-kreis gehoeren
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
ES2159529T5 (es) * 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9403909D0 (en) * 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
GB9702088D0 (en) * 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
TR199902562T2 (xx) * 1997-04-15 2000-02-21 Farmaceutisk Laboratorium Ferring A/S De�i�tirilmi� TNF alfa molek�lleri
EP0980258A1 (en) * 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115804821A (zh) * 2022-12-19 2023-03-17 新疆维吾尔药业有限责任公司 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用
CN115804821B (zh) * 2022-12-19 2024-05-14 新疆维吾尔药业有限责任公司 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用

Also Published As

Publication number Publication date
US20010021381A1 (en) 2001-09-13
JP2011006464A (ja) 2011-01-13
US20060222646A1 (en) 2006-10-05
ATE488250T1 (de) 2010-12-15
CA2364026A1 (en) 2000-09-08
DK1159003T3 (da) 2011-02-07
JP2002538170A (ja) 2002-11-12
WO2000051637A1 (en) 2000-09-08
CA2364026C (en) 2012-08-21
EP1159003B1 (en) 2010-11-17
US20020119152A1 (en) 2002-08-29
AU756677B2 (en) 2003-01-23
AU3386100A (en) 2000-09-21
DE60045240D1 (de) 2010-12-30
EP1159003A1 (en) 2001-12-05

Similar Documents

Publication Publication Date Title
JP2011006464A (ja) 喘息の治療における抗−ＴＮＦα抗体
ES2507542T3 (es) Anticuerpo anti-factor B humanizado
ES2186796T5 (es) Procedimientos para el tratamiento del asma alergica.
ES2327830T3 (es) Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
ES2701093T3 (es) Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
KR101605861B1 (ko) Ｉｌ－２５에 대한 항체
JP5992843B2 (ja) 抗ＩＬ−１α抗体による癌の処置方法
ES2274865T5 (es) Anticuerpos recombinantes para la interleuquina-1 beta humana.
KR101659452B1 (ko) Ｉｌ－２５에 대한 항체
PT1713503E (pt) Inibição do factor b, a via alternativa do complemento e métodos relacionados
MXPA06014299A (es) Anticuerpos contra interleucina-13 humana y uso de los mismos.
JP7458790B2 (ja) Ｉｌ－６阻害剤を含有する喘息の治療剤
US11690912B2 (en) Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
BR112021002794A2 (pt) anticorpo anti-il-1beta e composição farmacêutica do mesmo e uso do mesmo
WO2023061472A1 (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
CN115501347A (zh) 抗her2抗体药物偶联物和parp抑制剂联合在制备治疗肿瘤的药物中的用途
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
ES2985731T3 (es) Tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica mediante antagonismo de IL-20R
ES2357749T3 (es) Anticuerpos anti-tnf alfa en la terapia del asma resistente a esteroides.
US20260001949A1 (en) Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction
WO2021018191A1 (zh) Il-17拮抗剂治疗自身免疫疾病的方法
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
TW202130364A (zh) 以介白素２４或介白素２０拮抗劑治療組織纖維化和／或損傷和／或器官衰竭
CN121889423A (zh) 使用抗gfral抗体治疗恶心和呕吐病症的方法
CN116490520A (zh) 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法